Future Science Group

Future Science launches Therapeutic Delivery

TDE Cover

Therapeutic Delivery is the latest title to join the
Future Science portfolio – a series of peer-reviewed journals targeted at research and development professionals in healthcare and environmental communities. The journal launches in July 2010.

Over the past decade there has been a revolution in the development of therapeutic entities that are far removed from traditional small-molecule drugs, which have often been relatively easy to deliver to the site of action in patients. New complex and subtle entities, such as cell-based therapeutics and biopharmaceuticals – including proteins, peptides and nucleotides – present scientists with new challenges in terms of delivery science and technology. This evolving field has already yielded diverse techniques, including injectors, controlled release formulations, drug eluting implants and transdermal patches. Rapid technological advances and the desire to improve the efficacy and safety profile of existing medications by specific targeting to the site of action, combined with the drive to improve patient compliance, continue to fuel rapid research progress.

Therapeutic Delivery will provide researchers dedicated to this field with a forum for the rapid publication of original research and critical reviews of the latest developments. Coverage focuses on how the technological, pharmacological, clinical and physiological aspects come together to successfully deliver modern therapeutics to patients.

The editorial direction of Therapeutic Delivery is driven by a team of thirteen Associate Editors and an Advisory Panel of more than thirty international experts spanning the relevant disciplines, such as biology, chemistry, pharmacology and pharmaceutics, nanotechnology, physiology, materials science and engineering.

Dr John Patton, President and CEO, Dance Pharmaceuticals, Inc, USA said “The frustrating and costly rejection of painstakingly developed therapeutic delivery systems by biology is all too common. The integration of a strong biological perspective into therapeutic delivery research and development has often lagged behind highly innovative bench-top drug delivery innovations in chemistry, biochemistry and devices.” He concluded that, “….Therapeutic Delivery aims to cover all aspects of delivery from bench to bedside and thereby help to elevate the field to the premier place it should be in Medicine.”

Dr Mehul Mehta, Office of Clinical Pharmacology, US FDA also commented “As the name indicates, the scope of Therapeutic Delivery is indeed vast and ambitious. And every issue will be a comprehensive delivery!" Dr Mehta went onto say “Therapeutic Delivery will be a wonderful addition to our list of essential journals."

All articles submitted to the journal are subject to peer review by three, or more, independent assessors. Elisa Manzotti, Editorial Director at Future Science said, “There has been a phenomenal response to requests for manuscript submissions, indicating just how much interest there is in this exciting field. Our launch issue contains more than two hundred pages of insightful commentary”.

She added, “I am delighted with Therapeutic Delivery and although the ideal delivery of therapeutics may be many years away, I believe that this new journal will make an important contribution to this ultimate goal in the care of patients by bringing focus to the challenges through expert reviews and high-quality scientific papers.”

Therapeutic Delivery publishes reviews, original research, perspectives, commentary and news & views. The published articles in Therapeutic Delivery are in a highly accessible format - the contents can be viewed at www.future-science.com/loi/tde.

For complimentary access to all articles in the launch issue please contact
Craig Canham, +44 (0) 20 8371 6092; c.canham@future-science.com